AbbVie: Rocky Near-Term, Positive Long-Term
AbbVie outperformed the healthcare sector in 2025, but it remains to be seen whether the stock can repeat its performance in 2026. Last year, the stock was supported by relief for the pharmaceutical s...
Fiscal Year: January - December
AbbVie Inc. (ABBV), listed on the NYSE, has a market capitalization of $. As of Jan 05, 2026, the stock is trading at $229.31 per share, offering investors a clear view of its current market value. AbbVie Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 173.64, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. AbbVie Inc. also offers a dividend yield of 3.02%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that AbbVie Inc. (ABBV) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for AbbVie Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for AbbVie Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for AbbVie Inc. is 20.59, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, AbbVie Inc. (ABBV) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether AbbVie Inc. (ABBV) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of AbbVie Inc. (ABBV) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of AbbVie Inc.. To access the full SS Score, consider upgrading your subscription.
AbbVie Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 173.64. Investors should compare these metrics with industry peers to gauge whether AbbVie Inc. is outperforming or underperforming within its sector.
AbbVie outperformed the healthcare sector in 2025, but it remains to be seen whether the stock can repeat its performance in 2026. Last year, the stock was supported by relief for the pharmaceutical s...
The U.S. government is increasingly funding deficits with short-term debt, making interest expenses highly sensitive to Fed policy. A declining average maturity in the sovereign bond index tightens th...
AbbVie earns a buy rating, with strong 2025 EPS growth driven by Skyrizi and Rinvoq, despite pipeline concerns and a higher P/E. ABBV's valuation remains attractive; a 14.4x FY 2027 multiple is compel...
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%...
Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long...
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...
Our portfolios underperformed during the quarter and trail year to date. Health care was the primary hindrance as a result of our underweight in biotech and negative stock selection. We have materiall...
AbbVie earns a Strong Buy rating, driven by exceptional execution post-Humira patent cliff and robust 2025 share price outperformance. Skyrizi and Rinvoq are rapidly replacing Humira, delivering 47% a...
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics' Role in ABBV-230 Development While Preserving ...
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Data being presented showcases AbbVie's breadth and depth of research across a range of therapeutic modalities such as T-Cell Engagers, BCL-2 Inhibitors and Antibody-Drug Conjugates for a spectrum of ...
AbbVie (ABBV) remains a "Strong Buy" due to robust growth in immunology and neuroscience portfolios, offsetting Humira's decline. ABBV's oncology segment is poised for expansion with trispecific antib...
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,...
MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC).
MONTREAL, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV), jointly with the adMare BioInnovations, announced the launch of the AbbVie Biotech Innovators Award, a prize to help foster inno...
NORTH CHICAGO, Ill. , Nov. 24, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025.
- EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy available for patients with relapsed or refractory follicular lymphoma aft...
Investors can now access 4–7% from top-quality REITs, 3.5%+ from dividend ETFs, and 6%+ from midstream infrastructure — without taking on excessive risk. While the S&P 500 is up ~110% since 2020, 70–8...
AbbVie Inc. ( ABBV) 7th Annual Healthcare Symposium November 14, 2025 11:55 AM EST Company Participants Michael Paas Conference Call Participants Elena Meng Michelle Kehily Stephen Morse Magdalena So...
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
As a leader in migraine treatment, AbbVie is committed to addressing the impact of migraine in the workplace. 2025 honorees represent a diverse group of achievers—from teachers and authors to small bu...
AbbVie Inc (NYSE:ABBV) experienced a significant Power Inflow alert, a key bullish indicator that is closely tracked by traders who value order flow analytics, specifically institutional and retail or...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 21.89B | 22.75% | Est @22.8% |
| 2026 | 25.95B | 18.54% | Analyst x4 |
| 2027 | 27.93B | 7.66% | Analyst x5 |
| 2028 | 29.57B | 5.86% | Analyst x4 |
| 2029 | 31.77B | 7.42% | Analyst x3 |
| 2030 | 32.35B | 1.83% | Analyst x3 |
| 2031 | 32.87B | 1.61% | Est @1.6% |
| 2032 | 33.48B | 1.86% | Est @1.9% |
| 2033 | 34.16B | 2.04% | Est @2.0% |
| 2034 | 34.85B | 2.02% | Est @2.0% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 22.06B | 1.00 | 22.06B |
| 2024A | 17.83B | 1.00 | 17.83B |
| 2025E | 21.89B | 1.07 | 20.38B |
| 2026E | 25.95B | 1.15 | 22.49B |
| 2027E | 27.93B | 1.24 | 22.54B |
| 2028E | 29.57B | 1.33 | 22.21B |
| 2029E | 31.77B | 1.43 | 22.21B |
| 2030E | 32.35B | 1.54 | 21.06B |
| 2031E | 32.87B | 1.65 | 19.92B |
| 2032E | 33.48B | 1.77 | 18.89B |
| 2033E | 34.16B | 1.90 | 17.94B |
| 2034E | 34.85B | 2.05 | 17.04B |
| Terminal | 726.44B | 2.05 | 355.18B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.